Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

l trial for elagolix, the  most advanced clinical program in the Company's pipeline, will fail to support the additional Phase III clinical trial required for regulatory approval; risk that the elagolix Phase III program overall will encounter delays for regulatory or other reasons; risk that the elagolix Phase III clinical program will fail to demonstrate that elagolix is safe and effective for the treatment of endometriosis or support filings for regulatory approval; risk that the uterine fibroid elagolix clinical trials will fail to demonstrate that elagolix is safe and effective for the treatment of uterine fibroids; and  risks associated with the Company's dependence on corporate collaborators for Phase III development, commercial manufacturing and marketing and sales activities. In addition, the Company faces risks and uncertainties with respect to the rest of the Company's R & D pipeline including risk that the Company's clinical candidates will not be found to be safe and effective; risk that NBI-98854 will not proceed to later stage clinical trials and risk that the Company's clinical trials will fail to demonstrate that NBI-98854 is safe and effective; and risk that the Company's research programs will not identify pre-clinical candidates for further development. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's repor
'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... CannLabs, Inc. (OTCQB: CANL), ... scientific testing methodologies relating to cannabis, today announced that ... of credit from an existing stockholder of the Company. ... this commitment from one of our existing stockholders,” stated ... capital will help accelerate our planned expansions into the ...
(Date:11/22/2014)... -- The element of surprise has been a major advantage ... warning. Until now, epidemiologists had nothing to measure that ... in suboptimal responses to both the H1N1 pandemic of ... - http://photos.prnewswire.com/prnh/20141121/160242 That virus ... gene structural changes have been found that invariably to ...
(Date:11/21/2014)... Diego, CA (PRWEB) November 20, 2014 ... extended their Sartorius Entris Balance promotion . The ... customers seeking a durable, high accuracy, and easy-to-maintain balance ... made in Germany. It was designed to help customer’s ... affordable and a balance that is very durable. Sartorius ...
(Date:11/21/2014)... BlueInGreen, LLC ( BlueInGreen® ) ... and PCI, Inc., leading suppliers of ozone process ... selected to provide a new state-of-the-art ozone system ... Noland Wastewater Treatment. The new ozone disinfection ... gas dissolution technology, Pinnacle Ozone’s industry leading Zenith™ ...
Breaking Biology Technology:CannLabs Secures $750,000 Line Of Credit 2Viruses' Advantage of Surprise is Lost 2Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4
... ShapeGrabber and Nikon,Instruments Inc. today announced ... a,sales distribution channel in the United States ... inspection systems. This arrangement will,increase ShapeGrabber,s current ... Nikon to provide customers with,additional non-contact solutions ...
... Mr. Stewart brings critical experience in strategic and operational leadership ... ... opportunities, COLUMBIA, Md., April 8, 2008 ... of the Company. Cylex is a,global life sciences company that develops ...
... Fla., April 8, 2008 GeoPharma, Inc.,(Nasdaq: ... today at the,EdgeWater Research Partners Spring Conference being ... 2:25 MT., "We are thoroughly pleased to ... President David Lavigne. "GeoPharma has a,unique story with ...
Cached Biology Technology:ShapeGrabber and Nikon Instruments Inc. Announce Distribution Agreement 2Cylex Announces Brad L. Stewart as President of the Company 2GeoPharma to Present at EdgeWater Research Partners Conference 2
(Date:11/15/2014)... 2014  While we may still be a few years ... "Star Trek" to gain instant access to all that ailed ... smartphones and tablets for monitoring and measuring our health are ... may seem a tad Orwellian to some, but a new ... these technological opportunities into their healthcare regime. These ...
(Date:11/7/2014)... conjunction with the Glendale and ... the Verdugos has announced the " GLENDALE - ... to keep the Verdugo Regional Crime Lab operational after its ... existence, the Lab has processed more than 400 DNA samples, ... "Because our number one priority is the wellbeing of ...
(Date:11/6/2014)... - Insilico Medicine, Inc, a Baltimore-based bioinformatics company ... diseases announced a research collaboration with the international ... Inc (OTC: CSBR). , "There are many companies ... Champions Oncology,s TumorGraft technology is unique in a ... experimentally generating vast amounts of valuable data. Our ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... press release is available in German . ... ecological impact of the extended cultivation of energy crops. ... assessing the impacts and comparing the effectiveness of strategies ... The extension of bioenergy leads to problems to biological ...
... larvae is central to fully understanding and modeling the pelagic ... time, a numerical study conducted by the University of Miami ... flow fields, creating a powerful tool that spells out how ... the reef after being out on the open ocean. ...
... Analysis of ancient mitochondrial DNA (mtDNA) has been used ... cultures during the time before Christopher Columbus sailed to ... access journal BMC Genetics has used more ... identify the family relationships and burial traditions of ancient ...
Cached Biology News:How the ecological risks of extended bioenergy production can be reduced 2How the ecological risks of extended bioenergy production can be reduced 3Fish larvae find the reef by orienting: The earlier the better 2Fish larvae find the reef by orienting: The earlier the better 3Forensic science used to determine who's who in pre-Columbian Peru 2
Mouse monoclonal antibody raised against a partial recombinant TPR. NCBI Entrez Gene ID = TPR...
... for 1,464 array sample elements. , , ,Includes:, ... BSA in PBS (10X): 50 ml , INDIA HisProbe ... packs , 10% Tween-20: 2 x 10 ml ampules ... ml , SuperSignal West Pico Stable Peroxide: 2 ...
... system, 100-120 V, is used for biolistic ... handheld device employs an adjustable helium pulse ... gold microcarriers from the inner wall of ... cells. This system has a 2 square-centimeter ...
... Mouse polyclonal antibody raised ... Immunogen: ... 94 a.a) partial recombinant protein ... Accession Number: NM_024721 ...
Biology Products: